229 related articles for article (PubMed ID: 24399021)
41. [Clinical and biological features in refractory anemia with ringed sideroblasts with fluctuant platelet counts].
Ji O; Shen Q; Lin L; Zhang YC; Ji JM; Wu Y; Chen JY; Zhu GR; Kong XT; Xia W; Jiang PJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1036-41. PubMed ID: 20723324
[TBL] [Abstract][Full Text] [Related]
42. Refractory anemia with ringed sideroblasts and chronic myelomonocytic leukemia: myelodysplastic/myeloproliferative disease.
D'Angelo G
Lab Hematol; 2005; 11(3):171-3. PubMed ID: 16174602
[TBL] [Abstract][Full Text] [Related]
43. Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
Visconte V; Tabarroki A; Hasrouni E; Maciejewski JP; Hsi ED; Tiu RV; Rogers HJ
Leuk Lymphoma; 2016; 57(1):212-5. PubMed ID: 25926061
[No Abstract] [Full Text] [Related]
44. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
[No Abstract] [Full Text] [Related]
45. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation.
Szpurka H; Gondek LP; Mohan SR; Hsi ED; Theil KS; Maciejewski JP
Leukemia; 2009 Mar; 23(3):610-4. PubMed ID: 18818701
[No Abstract] [Full Text] [Related]
46. Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.
Cazzola M; Malcovati L
Hematology Am Soc Hematol Educ Program; 2015; 2015():19-25. PubMed ID: 26637696
[TBL] [Abstract][Full Text] [Related]
47. MDS/MPN-RS-T justified inclusion as a unique disease entity?
Montalban-Bravo G; Garcia-Manero G
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
[TBL] [Abstract][Full Text] [Related]
48. Refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T).
Mohamed M
Blood; 2014 Jan; 123(3):314. PubMed ID: 24575445
[No Abstract] [Full Text] [Related]
49. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
Aoyama Y; Sakai K; Kodaka T; Tsunemine H; Nishio K; Itoh T; Inoue D; Takahashi T
J Clin Exp Hematop; 2019 Mar; 59(1):29-33. PubMed ID: 30726782
[TBL] [Abstract][Full Text] [Related]
50. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease.
Pérez Sánchez I; Pérez Corrala A; Menarguez Palanca J; Mayayo Crespo M; Escudero Soto A; Pintado Cros T
Leuk Lymphoma; 2003 Mar; 44(3):557-9. PubMed ID: 12688334
[TBL] [Abstract][Full Text] [Related]
51. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis.
Tefferi A; Al-Kali A; Begna KH; Patnaik MM; Lasho TL; Rizo A; Wan Y; Hanson CA
Blood Cancer J; 2016 Mar; 6(3):e405. PubMed ID: 26967822
[No Abstract] [Full Text] [Related]
52. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts.
Nearman ZP; Szpurka H; Serio B; Warshawksy I; Theil K; Lichtin A; Sekeres MA; Maciejewski JP
Am J Hematol; 2007 Dec; 82(12):1076-9. PubMed ID: 17654685
[TBL] [Abstract][Full Text] [Related]
53. Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Zhang M; You Y; Li X; He Y; Zheng J; Li W; Zou P; Liu X; Liu F
Leuk Lymphoma; 2013 Jul; 54(7):1544-6. PubMed ID: 23252419
[No Abstract] [Full Text] [Related]
54. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Kern W; Bacher U; Schnittger S; Alpermann T; Haferlach C; Haferlach T
Cytometry B Clin Cytom; 2013 May; 84(3):194-7. PubMed ID: 23283847
[TBL] [Abstract][Full Text] [Related]
55. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
Szpurka H; Jankowska AM; Makishima H; Bodo J; Bejanyan N; Hsi ED; Sekeres MA; Maciejewski JP
Leuk Res; 2010 Aug; 34(8):969-73. PubMed ID: 20334914
[TBL] [Abstract][Full Text] [Related]
56. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
[TBL] [Abstract][Full Text] [Related]
57. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
[TBL] [Abstract][Full Text] [Related]
58. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
59. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Schnittger S; Bacher U; Haferlach C; Dengler R; Kröber A; Kern W; Haferlach T
Leukemia; 2008 Feb; 22(2):453-5. PubMed ID: 17713548
[No Abstract] [Full Text] [Related]
60. [Myelodysplastic syndrome classification].
Ghariani I; Braham N; Hassine M; Kortas M
Ann Biol Clin (Paris); 2013; 71(2):139-44. PubMed ID: 23587576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
